GlassScriptPhysician profile
Brian L Hunter
NPI 1811976616
$5,568.80
in general payments reported to CMS, 2019-2025
29 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,334 · 2022: $1,220 · 2023: $718 · 2024: $1,296 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $602.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $551.38 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $546.32 | 2022-2025 | Airsupra, Farxiga |
| Pfizer INC. | $439.17 | 2021-2025 | |
| Lilly USA, LLC | $429.13 | 2021-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $354.45 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.66 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $239.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $225.53 | 2021 | |
| Novo Nordisk INC | $161.23 | 2021-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $143.93 | 2021-2023 | Trintellix |
| Amgen INC. | $114.69 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $99.12 | 2022-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $84.79 | 2021-2025 | Ajovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.76 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.45 | 2021-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $42.28 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $41.61 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $36.70 | 2021 | |
| Dexcom, INC. | $28.42 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.14 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $17.04 | 2023 | Gvoke Hypopen |
| Lexicon Pharmaceuticals, INC. | $16.98 | 2023 | Inpefa |
| Ardelyx, INC. | $16.19 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $12.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.50 | 2022 | |
| Amarin Pharma, INC. | $12.14 | 2021 | |
| Genentech USA, INC. | $3.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.